Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist, Disease Biology

Employer
Intellia Therapeutics
Location
Cambridge, MA, United States
Start date
Oct 16, 2020

View more

Discipline
Science/R&D, Biotechnology, Pathology
Required Education
Masters Degree/MBA
Position Type
Full time
Hotbed
Genetown

Job Details

Our mission:

Developing curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

At Intellia, we are committed to solving the complex challenges of making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to create novel engineered cell therapies for immuno-oncological and autoimmune diseases.

Our Disease biology team is looking for a Scientist to lead projects related to the application of CRISPR/Cas9 for genetic disease. The Scientist will be responsible for developing, optimizing, and executing in vitro assays in support of our drug discovery activities, in both hepatic and extrahepatic settings. The ideal candidate will be experienced in developing cell-based and biochemical assays for mechanistic characterization of therapeutic targets and drug candidates. The candidate must exhibit strong interpersonal communication and organizational skills, eagerness to learn about new disease areas and techniques, and motivation to lead a cross-functional team in delivering reliable scientific data in a timely manner. The successful candidate will be able to leverage her/his existing experience with cell and tissue culture, gene expression analysis (e.g., qPCR, ddPCR), Western blotting, ELISA, and bioassay development. Creativity and intellectual curiosity are essential to the role, as is the ability to generate new therapeutic ideas and to distill complicated concepts into easy-to-understand and testable hypotheses.

Responsibilities
    • Lead cross-functional, disease-focused project teams from initiation to DC stage
    • Communicate effectively within functional team and across a matrixed organization
    • Develop in vitro assays to interrogate biological processes and test novel therapeutics
    • Perform cell culture with rodent, primate, and human primary cells and cell lines
    • Deliver high quality data to help advance drug discovery projects in the therapeutic portfolio
    • Analyze and interpret data, and troubleshoot experiments
    • Generate new therapeutic hypotheses leveraging CRISPR/Cas9 gene editing
    • Manage junior scientists on the team


Qualifications
    • MS degree in biology or a related discipline with 4+ years of relevant experience, or PhD degree with 2+ years of relevant experience
    • Ability to work and think independently and to contribute as a part of a highly matrixed team
    • Experience of leading a diverse project team to successfully achieve objectives
    • Cell culture, including with primary human cell types
    • qPCR/ddPCR, Western blotting, ELISA
    • Bioassay development, optimization and validation
    • Experience with CRISPR/Cas9 technology
    • Knowledge of inherited diseases of the liver, nervous system, bone marrow, and/or muscle
    • Prior experience supervising, mentoring and developing junior scientific staff


LI#DG1

What Intellia Stands For:

We push boundaries. We are focused on positively disrupting health care treatment of patients with genomic diseases. The values we live by and drivers we look for are:

- One is respect for individuals; our unique qualities and strengths; our own ways to understand, learn and improve. One is our single-minded determination to excel; to succeed together. One is you and us - trusting and counting on every single one of us.

- Explore because we seek new ways to tackle disease. Explore with unbounded minds...free from assumptions, open to ideas. Explore by staying curious, by pushing boundaries, overcoming obstacles. Explore means thinking of new ways.

- Disrupt by thinking courageously...and creating a better future. Disrupt by defying conformity; interrogating the status quo; questioning our momentum. Disrupt with challenging thoughts...with that breed of skepticism that shows you have better solutions.

- Deliver with your focus on the objective and your determination to complete the task. Deliver by advancing relentlessly and by maintaining high standards...even when nobody is watching. Deliver by staying accountable and pulling your weight. Deliver because patients are counting on us to make the promise reality. Get it done.

POSITION: Full-Time, Exempt

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Intellia's web-based application process is managed through Lever. Information submitted through application forms is collected by Lever and subject to Lever's privacy policy .

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert